Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Escherichia coli K88ab fimbrial antigen, also known as the F4ab adhesin, is a critical virulence factor found on the surface of enterotoxigenic Escherichia coli (ETEC) strains that primarily infect swine [1, 2]. These fimbriae are long, filamentous proteinaceous appendages composed of subunits, most notably the major subunit FaeG, which mediates the attachment of the bacteria to specific glycoprotein receptors on the brush border of porcine intestinal epithelial cells [2, 12]. This adhesion is the essential first step in the pathogenesis of neonatal and post-weaning diarrhea, allowing the bacteria to colonize the small intestine and deliver enterotoxins [1, 13]. Because of its pivotal role in infection, the K88ab antigen is a major target for the development of veterinary vaccines and passive immunization strategies [3, 7]. Therapeutic interventions, such as maternal vaccination or the administration of specific monoclonal antibodies, aim to block this adhesive interaction, thereby preventing colonization and the resulting clinical disease [5, 13]. The antigen exists in several variants (ab, ac, and ad), which presents a challenge for broad-spectrum vaccine efficacy due to immunological heterogeneity among the different serotypes [2, 15].
The primary mechanism of action involves the induction of neutralizing antibodies (IgA and IgG) or the use of competitive inhibitors to block the binding of the fimbrial adhesin to host intestinal receptors, thereby preventing bacterial colonization and subsequent enterotoxin-mediated diarrhea [1, 5, 13].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli K88ab fimbrial antigen (K88ab).